Key Financial Highlights (Consolidated Q1FY27)

Revenue Performance:

  • Total revenue: ₹257 crore for Q1FY27, representing 26% year-on-year growth
  • Export revenue grew by approximately 46% year-on-year
  • Gross profit: ₹203 crore with gross profit margin of 78.9% (100 bps improvement YoY)
  • EBITDA: ₹82 crore with EBITDA margin of 32.0% (190 bps improvement YoY)
  • PAT: ₹58 crore with PAT margin of 22.4% (80 bps improvement YoY)
  • Employee cost: ₹44 crore (34.2% increase YoY)
  • Other expenses: ₹77 crore
  • Depreciation: ₹18 crore
  • Other income: ₹13 crore
  • Finance cost: ₹0
  • Share in profit/(loss) in JV and Associates: ₹1 crore
  • Tax: ₹21 crore

Operational and Business Highlights

Growth Drivers:

  • Broad-based growth across all product categories
  • Increased wallet share among existing customers
  • Addition of new products to existing customers
  • Expansion of customer base with advanced discussions with large customers
  • Robust product pipeline targeting 2-3 product launches every year

Regulatory Approvals:

  • Received USFDA approval for ANDA for Mycophenolate Mofetil & Tofacitinib Tablets
  • Completed ANVISA inspection by Brazilian Health Regulatory Agency at manufacturing facility in Limbasi
  • Completed inspection by Pharmacy and Poisons Board (PPB) from Kenya at Unit-II formulation facility
  • Completed inspection by National Drug Authority (NDA) from Uganda at Unit-II formulation facility

Capacity Expansion:

  • Started commercial operations and sales at Stellon Biotech
  • Injectable business ramp-up with customer engagement at advanced levels

Sustainability Achievement:

  • Received EcoVadis Silver Medal, placing Concord among top 15% companies assessed globally

Business Segment Performance

API Business (FY26 Reference):

  • Revenue: Approximately ₹829 crore (79% of total revenue)
  • Portfolio: 30+ fermentation-based APIs across immunosuppressants, oncology, anti-infectives & anti-fungal
  • Key products include Tacrolimus, Mycophenolate Mofetil, Cyclosporine, Temsirolimus, Mupirocin, Vancomycin Hydrochloride

Formulation Business (FY26 Reference):

  • Revenue: Approximately ₹226 crore (21% of total revenue)
  • 180+ approved products across oral solid dosages and injectables
  • Operating through B2B model across regulated and emerging markets, B2B & B2C model for India market

CDMO Business:

  • Provides contract research and manufacturing services for developing APIs and formulations
  • DSIR-certified R&D facility with team of 180+ people
  • Expertise in fermentation technology and strong R&D infrastructure

R&D and Pipeline

  • Robust pipeline of more than 10 products across oncology, anti-infectives & anti-fungal therapeutic segments
  • Focus areas: cost improvement, new product development, process improvement, technology transfer, scale-up initiatives, enhancement of backward integration
  • State-of-the-art API R&D lab with specialized capabilities for strain isolation, mutation, and microbial strain selection
  • Formulations R&D lab with advanced analytical capabilities

Management Commentary

Mr. Ankur Vaid, Joint Managing Director & Chief Executive Officer, commented:

  • Strong revenue growth driven by broad-based performance across product categories and geographies
  • Export growth of 46% YoY reflects strong capabilities in delivering globally compliant products
  • Increased business from existing customers resulting in higher wallet share
  • Expansion of customer base and product portfolio strengthening growth pipeline
  • Successful regulatory inspections enhance regulatory credentials and global market readiness
  • Company positioned to consistently outperform industry growth through world's largest fermentation portfolio, regulatory compliance, and manufacturing capabilities
  • Focus on delivering sustainable long-term growth through compliance track record, differentiated product portfolio, and expanding customer relationships